SCHEMBL14728422

SCHEMBL14728422

Cc1c(CC2CCN(C(=O)OCc3ccccc3)CC2)c(C#N)c2nc3ccccc3n2c1N1CCC(C(N)=O)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.49
CYP2C19 P33261 2/20 0.49
ALDH1A1 P00352 6/20 0.45
HSD17B10 Q99714 4/20 0.45
HPGD P15428 3/20 0.45
CASP1 P29466 2/20 0.45
TSHR P16473 1/20 0.45
CASP7 P55210 1/20 0.45
GRIN2B Q13224 4/20 0.44
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
HIF1A Q16665 1/20 0.41
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
POLB P06746 1/20 0.40
KDM4E B2RXH2 2/20 0.40
ALOX15 P16050 1/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14728606 0.90 ALDH1A1 (0.46) SMN1; SMN2CYP2C19ALDH1A1HSD17B10HPGD
SCHEMBL14728426 0.89 MEN1 (0.49) SMN1; SMN2CYP2C19ALDH1A1HSD17B10HPGD
SCHEMBL14728427 0.88 ALDH1A1 (0.46) SMN1; SMN2CYP2C19ALDH1A1HSD17B10HPGD
SCHEMBL14728430 0.84 ALDH1A1 (0.49) SMN1; SMN2CYP2C19ALDH1A1HSD17B10HPGD
SCHEMBL14728440 0.82 SMN1; SMN2 (0.48) SMN1; SMN2CYP2C19ALDH1A1HSD17B10HPGD
SCHEMBL14728417 0.81 ALDH1A1 (0.45) SMN1; SMN2CYP2C19ALDH1A1HSD17B10HPGD
SCHEMBL14728555 0.81 ALDH1A1 (0.46) SMN1; SMN2CYP2C19ALDH1A1HSD17B10HPGD
SCHEMBL14728579 0.81 ALDH1A1 (0.53) SMN1; SMN2CYP2C19ALDH1A1HSD17B10HPGD
SCHEMBL14728416 0.80 ALDH1A1 (0.46) SMN1; SMN2CYP2C19ALDH1A1HSD17B10HPGD
SCHEMBL14728613 0.79 ALDH1A1 (0.48) CYP2C19ALDH1A1HSD17B10HPGDCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822688-B2 Imidazo[1,2-a]pyridine derivative ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
US-8822688-B2 Imidazo[1,2-a]pyridine derivative ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2013-02-28 US disclosed
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE PDE4B, PDE4A, PDE4C SMN1; SMN2 2352/4885CYP2C19 1314/4885ALDH1A1 1070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.